Endokrine Orbitopathie

 

 Buy Article Permissions and Reprints

Zusammenfassung

Die endokrine Orbitopathie (EO) ist Teil einer systemischen Autoimmunerkrankung (Prävalenz von 0,5 – 2 %), die eine Hyperthyreose, eine Orbitopathie, eine Akropachie und das prätibiale Myxödem umfasst (Morbus Basedow). Anti-TSH-Rezeptor-Antikörper spielen eine zentrale pathogenetische Rolle und hohe Spiegel sind mit einem schweren Krankheitsverlauf assoziiert. Kardinalsymptome der EO sind periorbitale Entzündung, Exophthalmos, verringerte Augenbeweglichkeit und erweiterte Lidspalten. Bei der Entstehung der Orbitopathie spielen die entzündlichen Reaktionen der Orbitafibroblasten die zentrale Rolle. Bei moderaten und schweren Verläufen ist eine antientzündliche Therapie (meist i. v. Steroidstoß und Orbitabestrahlung) und im Notfall eine Orbitadekompression indiziert. Bei milden Verläufen kann abgewartet oder Selen verabreicht werden. Operative Maßnahmen (Dekompression, Augenmuskelchirurgie, Lidchirurgie) haben im inaktiven Stadium die Wiederherstellung eines normalen Aussehens und der Funktion zum Ziel. Bei Rauchern tritt eine EO häufiger auf, verläuft schwerer und spricht schlechter auf die Therapie an. Die Normalisierung der Schilddrüsenfunktion führt bei mehr als der Hälfte der Patienten zu einer Verbesserung der EO.

Abstract

Graves’ orbitopathy (GO) is part of an autoimmune systemic disease (prevalence of 0.5 – 2 %) which is composed of hyperthyroidism, orbitopathy, dermopathy and acropachy. Stimulating antibodies against the TSH receptor plays the central pathogenetic role and high levels indicate the risk of a severe course of the disease. The main symproms of GO comprise soft tissue inflammation, proptosis impairment of ocular motility and lid retraction. Inflammatory reactions of orbital fibroblasts are responsible for the symptoms. To restrict damage, anti-inflammatory therapy (mainly i. v. systemic steroids, orbital irradiation) is indicated in moderate to severe active disease stages, and surgical orbital decompression is indicated in sight-threatening states. In mild GO selenium administration and otherwise a wait and see strategy is sufficient. In inactive disease stages surgery (orbital decompression, eye muscle surgery and lid surgery) is performed to improve appearance and function. Smoking increases the prevalence and severity of GO and reduces the efficiency of therapy. Restoring euthyroidism leads to an improvement of GO in about 60 % of the patients.

Literatur

• 1 Gianoukakis A G, Smith T J. Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy.  Curr Opin Endocrinol Diabetes Obes. 2008;  15 446-452
  Google Scholar
• 2 Bartley G B, Fatourechi V, Kadrmas E F et al. Chronology of Graves’ ophthalmopathy in an incidence cohort.  Am J Ophthalmol. 1996;  121 426-434
  Google Scholar
• 3 Eckstein A, Loesch C, Glowacka D et al. Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetric Graves ophthalmopathy.  Br J Ophthalmol. 2009;  93 1052-1056
  Google Scholar
• 4 Khoo D H, Eng P H, Ho S C et al. Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.  Thyroid. 2000;  10 1093-1100
  Google Scholar
• 5 Eckstein A K, Lax H, Losch C et al. Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission.  Clin Endocrinol. 2007;  67 607-612
  Google Scholar
• 6 Bartley G B, Fatourechi V, Kadrmas E F et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort.  Am J Ophthalmol. 1996;  121 284-290
  Google Scholar
• 7 Wiersinga W, Kahaly G. Graves’s ophthalmopathy. A multidisciplinary approach. Karger; 2007
  Google Scholar
• 8 Wiersinga W M, Perros P, Kahaly G J et al. Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers.  Eur J Endocrinol. 2006;  155 387-389
  Google Scholar
• 9 Mourits M P, Prummel M F, Wiersinga W M et al. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy.  Clin Endocrinol. 1997;  47 9-14
  Google Scholar
• 10 Perros P, Kendall-Taylor P. Natural history of thyroid eye disease.  Thyroid. 1998;  8 423-425
  Google Scholar
• 11 Bartalena L, Baldeschi L, Dickinson A et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.  Eur J Endocrinol. 2008;  158 273-285
  Google Scholar
• 12 Marcocci C. EUGOGO amo . Placebo-controlled trial of pentoxifylline v. selenium in mild Graves’ orbitopathy (GO).  N Engl J Med. 2011;  accepted
  Google Scholar
• 13 Kahaly G J, Pitz S, Hommel G et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy.  J Clin Endocrinol Metab. 2005;  90 5234-5240
  Google Scholar
• 14 Marcocci C, Bartalena L, Tanda M L et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study.  J Clin Endocrinol Metab. 2001;  86 3562-3567
  Google Scholar
• 15 Mourits M P, Kempen-Harteveld M L, Garcia M B et al. Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study.  Lancet. 2000;  355 1505-1509
  Google Scholar
• 16 Terwee C B, Prummel M F, Gerding M N et al. Measuring disease activity to predict therapeutic outcome in Graves’ ophthalmopathy.  Clin Endocrinol. 2005;  62 145-155
  Google Scholar
• 17 Le Moli van R, Baldeschi L, Saeed P et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves’ ophthalmopathy.  Thyroid. 2007;  17 357-362
  Google Scholar
• 18 Garrity J A, Fatourechi V, Bergstralh E J et al. Results of transantral orbital decompression in 428 patients with severe Graves’ ophthalmopathy.  Am J Ophthalmol. 1993;  116 533-547
  Google Scholar
• 19 Kahaly G, Schrezenmeir J, Krause U et al. Ciclosporin and prednisone vs. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study.  Eur J Clin Invest. 1986;  16 415-422
  Google Scholar
• 20 Hegedus L, Smith T J, Douglas R S et al. Targeted biological therapies for Graves’ disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.  Clin Endocrinol. 2011;  74 1-8
  Google Scholar
• 21 Paridaens D, Bosch W A, Loos van der T L et al. The effect of etanercept on Graves’ ophthalmopathy: a pilot study.  Eye. 2005;  19 1286-1289
  Google Scholar
• 22 Wabbels van den B, Forl M. Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction.  Ophthalmologe. 2007;  104 771-776
  Google Scholar
• 23 Eckstein A, Mann K, Kahaly G J et al. Role of TSH receptor autoantibodies for the diagnosis of Graves’ disease and for the prediction of the course of hyperthyroidism and ophthalmopathy. Recommendations of the Thyroid Section of the German Society of Endocrinology.  Med Klin. 2009;  104 343-348
  Google Scholar
• 24 Bartalena L, Tanda M L, Piantanida E et al. Relationship between management of hyperthyroidism and course of the ophthalmopathy.  J Endocrinol Invest. 2004;  27 288-294
  Google Scholar
• 25 Baldeschi L. Small versus coronal incision orbital decompression in Graves’ orbitopathy.  Orbit. 2010;  29 177-182
  Google Scholar
• 26 Boergen K P. Schieloperation in Tropfanästhesie bei endokriner Orbitopathie.  Z prakt Augenheilk. 1993;  14 301-305
  Google Scholar
• 27 Esser J, Eckstein A. Ocular muscle and eyelid surgery in thyroid-associated orbitopathy.  Exp Clin Endocrinol Diabetes. 1999;  107 (Suppl 5) S214-S221
  Google Scholar
• 28 Eckstein A, Schulz S, Esser J. Is combined surgical correction of horizontal and vertical squint of value in graves’ ophthalmopathy?.  Klin Monatsbl Augenheilkd. 2004;  221 769-775
  Google Scholar
• 29 Eckstein A, Fischer M, Krueger C et al. Die Behandlung der schweren Endokrinen Orbitopathie (EO) mit Optikuskompression: Orbitadekompression und Dosierung der nachfolgend notwendigen Schieloperationen.  Z prakt Augenheilk. 2002;  23 325-330
  Google Scholar
• 30 Harvey J T, Anderson R L. The aponeurotic approach to eyelid retraction.  Ophthalmology. 1981;  88 513-524
  Google Scholar
• 31 Hintschich C, Haritoglou C. Full thickness eyelid transsection (blepharotomy) for upper eyelid lengthening in lid retraction associated with Graves’ disease.  Br J Ophthalmol. 2005;  89 413-416
  Google Scholar
• 32 Mourits M P, Koornneef L. Lid lengthening by sclera interposition for eyelid retraction in Graves’ ophthalmopathy.  Br J Ophthalmol. 1991;  75 344-347
  Google Scholar
• 33 Feldman K A, Putterman A M, Farber M D. Surgical treatment of thyroid-related lower eyelid retraction: a modified approach.  Ophthal Plast Reconstr Surg. 1992;  8 278-286
  Google Scholar

Prof. Dr. Anja Eckstein

Orthoptik, Universitäts-Augenklinik Essen

Hufelandstraße 55

45122 Essen

Phone: ++ 49/2 01/7 23 29 07

Fax: ++ 49/2 01/7 23 56 41

Email: anja.eckstein@uk-essen.de